Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHL

Exclusion Criteria

• •Pregnant or lactating women. Women of childbearing potential are required to have a negative pregnancy test
• •* NCI CTC Grade 3 or 4 infusion reaction to prior anti-CD20 antibodies (rituximab, veltuzumab, etc.)
• •* A known anti-antibody response to prior antiCD20 antibodies (HACA positive, HAHA positive, etc)
• •* Prior radioimmunotherapy, including Zevalin or Bexxar.
• •* Prior high-dose chemotherapy with peripheral blood stem cell transplant.
• •* Prior therapy with other human or humanized monoclonal antibodies, unless HAHA tested and negative
• •* Primary CNS lymphoma, HIV lymphoma or transformed lymphoma, or presence of symptomatic CNS metastases or carcinomatous meningitis.
• •* Rituximab or veltuzumab resistant, defined as having progressed during or within 6 months of any prior rituximab or veltuzumab treatment.
• •* Bulky disease by CT, defined as any single mass \>10 cm in its greatest diameter
• •* Bone marrow involvement ≥25%
• •* Prior external beam radiation therapy to \>30% bone marrow.
• •* Pleural effusion with positive cytology for lymphoma
• •* Patients known to be HIV positive, hepatitis B positive, or hepatitis C positive
• •* Known autoimmune disease or presence of autoimmune phenomena.
• •* Evidence of infection or requiring antibiotics within 7 days.
• •* Use of systemic corticosteroids within 2 weeks, except low dose regimens (prednisone, \<20 mg/day, or equivalent) which may continue if unchanged.
• •* Prior malignancies (other than non-melanoma skin cancer or carcinoma in situ of the cervix) unless disease free for 5 years.
• •* Prior malignancy with less than a 5-year disease-free interval, excluding nonmelanoma skin cancers and carcinoma in situ of the cervix.
• •* Other concurrent medical or psychiatric conditions that, in the Investigator's opinion, may be likely to confound study interpretation or prevent completion of study procedures and follow-up examinations